Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Safi Dokmak

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3335-4388; OpenAlex author ID A5102934960. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 5 papers · 2022: none · 2023: 2 papers · 2024: 5 papers · 2025: 8 papers · 2026: 3 papers

Papers 27

  1. Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectom… Last author DOI 10.1007/s00464-026-12991-3↗
  2. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  3. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  6. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… First author DOI 10.1016/j.hpb.2025.04.009↗
  7. Laparoscopic pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared with open pancreatoduode… Last author DOI 10.1016/j.surg.2024.09.041↗
  8. Laparoscopic compared with open pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy. Co-author DOI 10.1016/j.surg.2025.109281↗
  9. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  10. Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1177/17588359251403909↗
  11. Total Pancreatectomy for Locally Advanced Pancreatic Adenocarcinoma with Coeliac Trunk Resection and Retrograde Gastric Revascularization Through Aorto-Hepato-… Last author DOI 10.1245/s10434-024-16844-y↗
  12. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  13. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  14. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  15. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  16. Distal Pancreatectomy for Body Pancreatic Ductal Adenocarcinoma: Is Splenectomy Necessary? A Propensity Score Matched Study. Co-author DOI 10.1245/s10434-024-15220-0↗
  17. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  18. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  19. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  20. A Novel Pancreatic Fistula Risk Score Including Preoperative Radiation Therapy in Pancreatic Cancer Patients. Co-author DOI 10.1007/s11605-020-04600-y↗
  21. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Co-author DOI 10.1097/sla.0000000000003717↗
  22. Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential dia… Co-author DOI 10.1177/17588359211053412↗
  23. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  24. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  25. Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition o… Co-author DOI 10.1177/2050640618824910↗
  26. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients. Co-author DOI 10.1016/j.jviscsurg.2015.11.014↗
  27. Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: Time for a Randomized Controlled Trial? Results of an All-inclusive National Observati… Co-author DOI 10.1097/sla.0000000000001479↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alain Sauvanet Sauvanet · 12 shared papers, 2015–2026 · strength 2.31
  2. Mickaël Lesurtel · 6 shared papers, 2024–2026 · strength 1.64
  3. Louis de Mestier · 5 shared papers, 2019–2026 · strength 1.00
  4. Elias Karam · 3 shared papers, 2025–2026 · strength 0.89
  5. Jerome F. Cros · 5 shared papers, 2019–2025 · strength 0.88
  6. Vinciane Rebours · 4 shared papers, 2019–2025 · strength 0.83
  7. Giovanni Butturini · 5 shared papers, 2020–2024 · strength 0.53
  8. Ugo Boggi · 5 shared papers, 2020–2024 · strength 0.53
  9. Marc G. Besselink · 5 shared papers, 2020–2024 · strength 0.53
  10. Mohammad Abu Hilal · 5 shared papers, 2020–2024 · strength 0.53
  11. Olivia Hentic Dhome · 2 shared papers, 2025 · strength 0.51
  12. Maxime Ronot · 2 shared papers, 2025 · strength 0.47
  13. Alessandro Zerbi · 4 shared papers, 2020–2024 · strength 0.44
  14. Tobias Keck · 4 shared papers, 2020–2024 · strength 0.42
  15. Riccardo Casadei · 4 shared papers, 2020–2024 · strength 0.42
  16. Maarten Korrel · 4 shared papers, 2020–2024 · strength 0.42
  17. Jony van Hilst · 4 shared papers, 2020–2024 · strength 0.42
  18. Massimo Falconi · 4 shared papers, 2020–2024 · strength 0.42
  19. Bjørn Edwin · 4 shared papers, 2020–2023 · strength 0.39
  20. Sanne Lof · 4 shared papers, 2020–2023 · strength 0.39
  21. Matteo De Pastena · 3 shared papers, 2020–2024 · strength 0.33
  22. Andrea Pietrabissa · 3 shared papers, 2021–2024 · strength 0.33
  23. Bergþór Björnsson · 3 shared papers, 2021–2024 · strength 0.33
  24. Thilo Hackert · 3 shared papers, 2021–2024 · strength 0.33
  25. Bas Groot Koerkamp · 3 shared papers, 2021–2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.